Search
Varicella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalFirst approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as … Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in
Ferrous sulfate anhydrous
go.drugbank.com/drugs/DB13257ApprovedInvestigationalIt is the gold standard of oral iron therapy in the UK and many other countries.[L2234,L2246]
mRNA-1010
go.drugbank.com/drugs/DB22484ApprovedMFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza. … [L64058,L64059,L64060] Full approval applies to adults 50 through 64 years, while the indication for adults 65 years and older was granted accelerated approval based on immune responses, with clinical
Varicella zoster vaccine (live/attenuated)
go.drugbank.com/drugs/DB10318ApprovedInvestigationalThis is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. … Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801Approved[L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigational[L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits
Janssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … Follow-up preclinical studies in rhesus monkeys[A220058] showed that the Ad26 vaccine produced a robust response and provided near perfect protection in nasal swabs and bronchoalveolar lavage following
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Copper histidinate
go.drugbank.com/drugs/DB32041ApprovedIt was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC